A Second Baby Has Been Born Via Uterus Transplant in the U.S.

A second woman in the U.S. born without a uterus has given birth to a baby, thanks to a uterus transplant. The birth took place at Baylor University Medical Center at Dallas, a part of Baylor Scott &White, which performed the first birth via uterus transplant late last year. The baby, born in February, is a girl. The hospital is not revealing the identity of the mother, but says the pregnancy and birth were uncomplicated. The birth is the second in the hospital’s ongoing uterus transplant clinical trial. The women in the trial have absolute uterine factor infertility (AUI), which means their uterus is nonfunctioning or nonexistent. Like the first woman to give birth as part of the trial, the woman who gave birth in February has a condition called Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, which means she was born without a uterus and lived her life believing she would never be able to be pregnant or give birth. The woman was transplanted with a uterus from a living donor. Such procedures, while still experimental, could provide another option for families dealing with AUI, including women who have had their uterus removed for medical reasons like cancer. MORE: First U.S. Baby Born After a Uterus Transplant “Emotionally this was the same level of intensity [as the first birth],” says Dr. Giuliano Testa, the leader of the uterus transplant clinical trial at Baylor, and surgical chief of abdominal transplant for Baylor Annette C. and Harold C. S...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized fertility healthytime onetime Source Type: news

Related Links:

Immunotherapy has already revolutionized cancer care. Combining various immunotherapies promises even greater success, but will the already high cost of these therapies put combos out of reach?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
PROSTATE cancer symptoms don ’t always appear in the early stages until the tumour has grown and put pressure on other parts of the body. When this happens, pain in certain parts of the body may begin to show.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Parashar P, Tripathi CB, Arya M, Kanoujia J, Singh M, Yadav A, Kumar A, Guleria A, Saraf SA Abstract Co-therapy through biotin modified nanoparticles (NPs) of gefitinib (Gnb) and naringenin (Nar) was investigated for its therapeutic and synergistic potential against lung cancer. The biotin-conjugated polymeric NPs (bty-Nar/Gnb) were developed using oil in water emulsion technique and optimized using central composite design. The formulations were subjected to various in vitro (A549 cell lines) and in vivo evaluations in urethane-induced lung cancer. Co-administration of Gnb and Nar NPs displayed a signific...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
PROSTATE cancer symptoms don ’t always appear in the early stages until the tumour has grown and put pressure on other parts of the body. When this happens, pain in certain parts of the body may begin to show.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Report warns that health of children in England will continue to fall behind other European countries if current trends continue. Key infant mortality risk factors included higher proportion of young mothers, higher rates of smoking during pregnancy, and lower breastfeeding rates
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
After a double mastectomy, Catherine Guthrie wanted to retain her strength and challenge the idea of feminine norms.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Breast Cancer Women and Girls Mastectomy Surgery and Surgeons Muscles Source Type: news
ConclusionCRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Declan Dunne, Claire Knowles
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Liz Baker, Norma Robinson, Mohamed Tabaqchali, David Leaper
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Liz Baker, Louise Hall, Deborah Wilson, Pud Bhaskar
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Babies | Cancer | Cancer & Oncology | Cancer of the Uterus | Clinical Trials | Girls | Health | Hospitals | Infertility | Insurance | Insurers | Learning | Men | MRKH Syndrome | Ovarian Cancer | Ovaries | Pregnancy | Reproduction Medicine | Study | Sweden Health | Transplant Surgery | Transplants | Universities & Medical Training | USA Health | Women